ClinicalTrials.gg
CompletedNCT05055726BOOMUpdated Nov 16, 2022

Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

A Phase 4 interventional study of Benzydamine Hydrochloride 0.15% w/v oromucosal solution in Radiation-Induced Mucositis and Head and Neck Cancer, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Head and Neck Neoplasms with a site in Hungary — 4 open to participants now, 8 under way, 4 of them phase 3. Head and Neck Neoplasms · Hungary.

Enrollment
24th of 32
100 · median 301
Started
2021
with 3 others
Phase 4
Only one
of the 34
Registered
28th of 34
by date
Lead sponsor
1 of 34
Aziende Chimiche Riunite Angelini Francesco S.p.A

Among the 34 studies in Head and Neck Neoplasms with a site in Hungary, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 4, and was the 28th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

4 of the 34 studies in Head and Neck Neoplasms with a site in Hungary are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Head and Neck Neoplasms with a site in Hungary, or all of them as a file.
02

Study summary

The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.

Read the detailed description

This is a phase IV clinical study whose aim is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with Head and Neck cancer.

Benzydamine mouthwash is considered the gold standard among anti-inflammatory agents in the management of oral mucositis in cancer patients.

The 2014 mucositis guidelines recommended benzydamine mouthwash for the prevention of radiation-induced oral mucositis among Head and Neck Cancer patients treated with moderate doses of radiation therapy. The updated 2019 guidelines not only confirm the existing guidelines proving new evidences, but also recommend to use benzydamine as preventative treatment of radiation-induced Oromucositi among Head and Neck Cancer. patients treated with radiation therapy with/without systemic concurrent treatments and confirm benzydamine mouthwash as the only anti-inflammatory agent with evidence in prevention of oral mucositis to date.

03

Conditions studied

  • Radiation-Induced Mucositis
  • Head and Neck Cancer

Keywords

  • oral mucositis
  • radiation therapy
  • head and neck cancer
  • mouthwash
  • oromucosal solution
  • benzydamine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients of any ethnic origin ≥18 years of age.
  • Patients diagnosed with stage III or IV Head and Neck cancer (histologic or cytologic diagnosis), according to VIII AJCC staging system, who are candidate and are about to start RT, with or without concomitant CT, with curative intent, either with exclusive or postoperative intent.
  • (ECOG) performance status with a score of 0, or 1, or 2.
  • Patients legally capable of giving their consent to participate in the study and available to sign and date the written and the Declaration of consent for the processing of personal data.
  • Women of or with no menses for a period \< 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the end of the study, using an appropriate method, such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:

    • Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming , unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  • Patients with reported allergy to benzydamine or another component of the formulation used.
  • Any listed in the local product's Summary of Product Characteristics (SmPCs).
  • Patients with prior head and neck RT (in the previous 6 months), or patient who received a palliative treatment.
  • Patients with distant disease and/or severe cognitive impairment and/or clinically symptomatic and/or patients with significant comorbid conditions.
  • Patients with mucositis due to other medical conditions (e.g., gastro-oesophageal reflux, disease, etc.).
  • Patients who use other oromucosal products (over the counter or prescription) for the same disease.
  • Prescription of other rinses (anaesthetics like "magic mouthwashes" or others), except from sodium bicarbonate rinses.
  • Use of chlorhexidine, other anti-inflammatory mouthwashes solutions, misoprostol, granulocyte macrophage colony-stimulating factor (GM-CSF) and sucralfate gel.
  • Employment of antifungal or antibiotic drugs as prophylaxis for mucositis; any therapeutic use in case of overt clinical infections is allowed.
  • Patients treated with other therapies that can cause mucositis, except for the therapies for their primary condition.
  • Patients treated with any topical anti-inflammatory/analgesic products for the mucositis.
  • Any other product that can interfere with the evaluation of pain or inflammatory state, according to the Investigator's assessment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Benzydamine Hydrochloride 0.15% w/v oromucosal solution

    Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis. The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC. In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day. In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds.

    Drug: Benzydamine Hydrochloride 0.15% w/v oromucosal solution

Interventions

  • DrugBenzydamine Hydrochloride 0.15% w/v oromucosal solution

    Drug page: Benzydamine

    Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.

06

What researchers measure

Primary outcomes

  1. Number of responders

    The effectiveness of benzydamine oromucosal solution (mouthwash) in the prevention/tratment of radiation-induced oral mucositis in Head and Neck cancer patients is evaluated as the number of responders, expressed in percentage, defined as the number of head and neck cancer patients with oral mucositis pain intensity \<5 in the Numeric Rating Scale.

    Time frame: Up to 7 weeks

Secondary outcomes

  1. Number of compliant patients to Benzydamine treatment.

    The compliance to the treatment is calculated at the end of the study. A patient is considered compliant to the benzydamine treatment if he/she takes ≥80% of the total dose assigned by the Investigator.

    Time frame: Up to 7 weeks

  2. Change score in the World Health Organization oral mucositis grading scale.

    The severity of oral mucositis is evaluated using the World Health Organization (WHO) oral mucositis grading scale. The Investigator gives a score corresponding to the grade of mucositis of the patient, from "0" = "None" to "4" = "Life-threatening", "Oral alimentation impossible".

    Time frame: Up to 7 weeks

  3. Number of days of duration of severe oral mucositis.

    The duration of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed.

    Time frame: Up to 7 weeks

  4. Time of onset of severe oral mucositis.

    Time of onset of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed.

    Time frame: Up to 7 weeks

  5. Percentage change in body weight

    The percentage change in body weight from baseline is assessed.

    Time frame: Up to 7 weeks

  6. Number of days of duration of Radiotherapy/Chemotherapy

    Radiotherapy/Chemotherapy is assessed as number of days of duration of therapy.

    Time frame: Up to 7 weeks

  7. Number of days of discontinuation of Radiotherapy/Chemotherapy

    Radiotherapy/Chemotherapy is assessed in terms of days of therapy discontinuation.

    Time frame: Up to 7 weeks

  8. Dose modifications of Radiotherapy/Chemotherapy

    Radiotherapy/Chemotherapy is evaluated as dose modifications of therapy.

    Time frame: Up to 7 weeks

  9. Delays in Radiotherapy/Chemotherapy

    Radiotherapy/Chemotherapy is evaluated as days of delay in therapy.

    Time frame: Up to 7 weeks

  10. Number of days of hospitalization.

    The healthcare resources consumed in terms of number of days of hospitalization due to oral mucositis are evaluated.

    Time frame: Up to 7 weeks

  11. Change in QoL (EORTC QLQ C-30) from baseline

    The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30)

    Time frame: Up to 7 weeks

  12. Change in QoL (EORTC QLQ-H&N35) from baseline

    The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck (EORTC QLQ-H\&N35).

    Time frame: Up to 7 weeks

  13. Number and type of opioid analgesics

    The use of opioid analgesics prescribed for oral mucositis pain is assessed.

    Time frame: Up to 7 weeks

  14. Frequency of adverse events

    AEs occurred during a clinical trial are assessed by the Investigator in terms of seriousness and relationship with the investigational product.

    Time frame: Up to 7 weeks

07

Study locations

10 sites
  • Orszagos Onkologiai Intezet, Gyogyszertar
    Budapest, 1122, Hungary
  • Debreceni Egyetem Klinikai Kozpont, Intezeti Gyogyszertar
    Debrecen, 4032, Hungary
  • Petz Aladar Egyetemi Oktato Korhaz, Intezeti Gyogyszertar,
    Győr, 9024, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz - Eszaki Tomb, 1. Emelet, 4. Szarny, Klinikai - Vizsgalati Egyseg.
    Kaposvár, 7400, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Klinikai Kutatasi Osztaly
    Nyíregyháza, 4400, Hungary
  • Csolnoky Ferenc Korhaz, Onkologiai Centrum Sugarterapias Osztaly
    Veszprém, 8200, Hungary
  • Centrum Onkologii im. Prof. Franciszka Łukaszczyka Apteka Szpitalna
    Bydgoszcz, 85-796, Poland
  • Szpitale Pomorskie Sp. z o. o.,
    Gdynia, 81-519, Poland
  • Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach -
    Siedlce, 08-110, Poland
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii im. M. Kopernika w Lodzi, - Lódzkie
    Łódź, 95-513, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Sep 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Sep 24, 2021
StartActual
Dec 6, 2021
Primary completionActual
Sep 5, 2022
CompletionActual
Sep 5, 2022
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05055726
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
Dec 6, 2021
Primary completion
Sep 5, 2022
Completion
Sep 5, 2022
Last update
Nov 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benzydamine

Start the discussion